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Summary
The IL-15 triggering effect of gliadin is not exclusive to coeliac disease (CD)
patients, whereas the secondary response is CD specific. We have studied the
expression of the IL-15 receptor, and the IL-15 response upon stimulation, in
non-CD and CD patients, and the possible existence of a lower immunological
threshold in the latter. Forty-two CD patients (20 on a gluten-containing diet,
GCD, and 22 on gluten-free diet, GFD) and 24 non-CD healthy individuals
were studied. IL15Ra mRNA expression, and tissue characterization, were
assayed in the duodenum. Biopsies from six CD patients on GFD and 10
non-CD individuals were studied in vitro using organ culture in basal
conditions, as well as after IL-15 stimulation discarding basal IL-15
production. Secretion of immune mediators was measured in the culture
supernatants. IL15Ra mRNA expression was increased in CD patients, as
compared with non-CD controls (on GFD P = 0·0334, on GCD P = 0·0062,
respectively), and confirmed also by immunofluorescence. No differences
were found between CD patients on GFD and on GCD. After in vitro IL-15
stimulation, IL15Ra expression was only triggered in non-CD controls
(P = 0·0313), though it remained increased in CD patients. Moreover, IL-15
induced a more intense immunological response in CD patients after trigger-
ing the production of both nitrites and IFNg (P = 0·0313, P = 0·0313,
respectively). Gliadin-induced IL15 has a lower response threshold in CD
patients, leading to the production of other immune mediators and the devel-
opment of the intestinal lesion, and thus magnifying its effects within the CD
intestine.
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Introduction
Coeliac disease (CD) is a small intestinal hypersensitivity to
wheat and other gluten-containing cereals (rye, barley and
probably oats) occurring in genetically predisposed indi-
viduals [1,2]. This immune-mediated enteropathy is charac-
terized by villous atrophy, crypt hyperplasia and increased
infiltration by intraepithelial lymphocytes [3]. Some gluten
peptides reach to the lamina propria, where some of them
are deaminated by the enzyme tissue transglutaminase
(TG2) [4] and presented on a HLA-DQ2 (or DQ8) context
by dendritic cells [5,6], with the subsequent induction of a
pro-inflammatory response, mainly characterized by IFNg
production. The current treatment is a life-long strict
gluten-free diet (GFD), which results in a complete remis-
sion of symptoms and mucosal histology [1,2].
Nowadays, the most accepted model for explaining the
immunopathogenesis of CD is the two-signal model [7].
Thus, innate immunity plays a key role, through a DQ2-
independent mechanism, in the development of CD [8,9]. In
this context, gliadin toxic peptides (i.e. the 19-mer) trigger
an innate immune response [10], mainly characterized by
the production of IL-15 by epithelial cells [11]. The result is
the disruption of the epithelial barrier, both by directly
increasing the permeability throughout the tight-junctions
[12,13], and by inducing enterocyte apoptosis after intra-
epithelial lymphocyte reprogramming into NK-like cells
[14–17]. As a consequence, immuno-adaptive peptides, like
the 33-mer, can now reach to the lamina propria, where they
are presented by dendritic cells to gluten-specific T cells [18],
acting as a bridge between the innate and the adaptive
immunity [19].
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This innate response has been proposed to be CD specific
[10], but no differential factors controlling this response
have been described so far. Moreover, by using a biopsy
culture model, we have previously shown that the IL-15
triggering effect of gliadin occurs in both CD patients and
non-CD healthy controls, though the adaptive immune
mediators were only elicited by CD patients [20].
As the first gluten-induced (innate) signal is observed in
both CD and non-CD individuals, whereas the second
(adaptive) signal appears specifically in CD patients, and
considering that duodenal biopsies of CD patients showed
an increased expression of IL15Ra [11], it is tempting to
speculate that the higher expression of this receptor has
a biological role in the immunopathogenesis of CD. Thus,
the gliadin-induced IL-15 production would lead to major
changes in CD patients, but it would be not enough to reach
the threshold response in non-CD patients.
To address this question, basal expression of IL15Ra
mRNA was determined in CD patients with active disease
and on a GFD, and in a group of healthy controls. Moreover,
given the higher expression of IL15Ra in CD patients, bio-
psies from both non-CD healthy controls and CD patients
on GFD were studied in vitro using organ culture in basal
conditions, and after IL-15 stimulation, in order to evaluate
the production of secondary immune mediators.
Materials and methods
Study subjects
We studied a total of 42 CD patients (mean age 21·24 years,
range 2–68 years, 30·95% males); 20 were untreated (mean
age 6·80 years, range 2–38, 30·00% males) and 22 treated on
a GFD (mean age 34·36 years, range 7–68 years, 31·82%
males). A group of 24 non-CD healthy individuals were
included in our study as controls (mean age 53·04 years,
range 16–81 years, 20·83% males). They were referred to the
Gastroenterology Clinics due to other intestinal pathologies,
which were later ruled out, and no mucosal changes were
found in the duodenum. The final diagnosis was non-CD in
all cases. At the time of diagnosis, all CD patients had com-
patible symptoms of the disease, positive serology (IgA
antiendomysial or antitransglutaminase antibodies), genet-
ics (HLA-DQ2/8), and mucosal changes in the duodenal
biopsy. At the time of sample collection, active CD patients
had positive serology and mucosal changes, whereas CD
patients on GFD had mucosal recovery (Marsh 0–1) and
negative serology for at least 1 year. The recruited patients
attended the Adult Gastroenterology Clinics at the ‘Hospital
Clínico Universitario’ in Valladolid, and the ‘Hospital Valle
del Nalón’ in Asturies, as part of the routine diagnostic
procedures. Informed consent was obtained from patients,
and the study protocol was approved by the Ethics Commit-
tee of both ‘Hospital Clínico Universitario’ and the Faculty of
Medicine, University of Valladolid.
Biopsy and specimen preparation
A total of 66 biopsies, 24 from healthy controls and 42 from
CD patients (20 on GFD and 22 on a gluten-containing diet)
were collected. They were immediately submerged in 0·5 ml
of RNALater ® solution (Ambion Inc., Austin, Texas, USA)
and stored at –20°C. Both total RNA and proteins were iso-
lated from each biopsy using the TRIZOL® reagent according
to the protocol provided by the manufacturer. Reverse tran-
scription was carried out by using the SuperScript® First-
Strand Synthesis System for reverse Transcriptase (RT)-PCR
Kit (Invitrogen, Life Technologies, Carlsbad, CA, USA) using
OligodT primers.
Organ culture of duodenal mucosa
Intestinal biopsies from 10 CD patients on GFD (mean age
43·64 years, range 23–68, 18·18% males) and 23 non-CD
healthy controls (mean age 53·04 years, range 16–81, 20·83%
males) were cultured in vitro as previously described [21].
Briefly, all biopsies were collected in ice-chilled PBS
(Cambrex Iberia Products, Barcelona, Spain) containing
0·1% Gentamicine (Cambrex) and cultured within 1 h in
RPMI 1640 (Cambrex) supplemented with 10% heat-
inactivated FBS (Cambrex), penicillin (100 U/mL), strepto-
mycin (100 mg/ml) (Cambrex) and fungizone (0·25 mg/ml)
(Cambrex). Seven CD patients on a GFD and 10 non-CD
healthy controls were also studied after IL-15 stimulation
with 50 ng/ml (Pierce Biotechnology Inc., Rockford, IL,
USA) (patients on GFD, mean age 47·71 years, range 25–68,
0% males; non-CD healthy controls mean age 53·6 years,
range 23–66, 10% males) (Table 1). In these cases, each
sample cultured in basal conditions constituted an internal
control. Tissue culture was carried out by immersion in
culture dishes placed in a cell incubator with 5% CO2 at 37°C.
After 3 hours, biopsy specimens were washed up in PBS
containing 0·1% Gentamicine (Cambrex) and later cultured
for another 21 h in new clean culture medium to determine
whether an innate stimulus is followed by a secondary
response. After 24 h (3 h with stimulus + 21 h of basal
medium), tissue was embedded in RNAlater (Ambion) and
snap-frozen until protein and RNA isolation extraction were
carried out as previously described.
Western blot analysis
Eight mg of protein isolated from whole biopsy explants
were added per well. They were separated by using a 15%
acrilamide/bisacrilamide (37·5:1) gel in a mini-Protean II
(BioRad Laboratories Inc., Hercules, CA, USA), and later
transferred onto PVDF membranes of 0·45 Micron (Pierce
Biotechnology Inc.). Membranes were incubated with
primary specific antibodies to human IL-15 (mouse mono-
clonal MAB247, R&D, Minneapolis, USA) at a final dilution
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of 1/400, performing a second incubation with antibodies to
mouse IgG labelled with horseradish peroxidase (Amersham
Biosciences Europe, Freiburg, Germany). Chemiluminiscent
substrate Lumigen PS-3 (Amersham) and autoradiography
film Hyperfilm ECL (Amersham) were used for developing.
Recombinant human IL-15 (Peprotech, London, UK) was
used as a positive control.
Immunofluorescence studies
Duodenal biopsies from three healthy controls and three CD
patients on a gluten-containing diet were also fixed in
Bowin’s medium and included in paraffin. Sections were
rehydrated and treated with antigen retrival solution (Dako,
Glostrup, Denmark). After two washes in PBS-Tween20
0·1%, samples were sequentially incubated with 50 mg/ml of
goat anti-IL15Ra (R&D), and donkey anti-goat IgG-Cy5
1:200 (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA). Images were taken in a LSM 510 meta Zeiss con-
focal microscopy using the LSM 5 v 3.2 software.
Quantitative polymerase chain reaction
mRNA levels of IL15Ra, iNOS, IFNg, TNFa and b-actin (as
a house keeping gene) were measured by real-time PCR by
using a LightCycler® instrument (Roche Applied Science,
Mannheim, Germany). As there are at least eight different
isoforms for IL15Ra and some of them are secreted [22],
IL15Ra reverse primer was localized between exons 6 and 7,
amplifying only non-secreted isoforms. Forward primer was
localized in exon 3, in the linker between the cytokine-
binding domain and the Pro/Thr rich domain [22].
Reactions were performed using the FastStart SYBR Green
MasterMix (Roche) with thermolabile Uracil DNA Glycosy-
lase (UDG) (Roche) to prevent carry-over contamination.
Cytokine primer sets and PCR conditions are described in
Table 2. mRNA levels are expressed as the ratio molecule/b-
actin in arbitrary units. Molecules showing not detectable
levels were given an arbitrary unit of 0·1.
Effector molecules on culture supernantants
According to the Griess Reagent kit for nitrite determination
(Molecular Probes, detection limit 1 mM), 3-h biopsy culture
supernatants were assayed following the manufacturer’s
instructions. Final supernatants (after 24 h of culture) were
also analysed by using a multiplex assay (Biorad, Hercules,
CA, USA) on a Luminex TM platform (Biorad, Austin, TX,
USA), following the manufacturer’s instructions, for the
concentration of interferon g (IFN-g) (detection limit (D.L.)
0·542 pg/ml), tumour necrosis factor a (TNF-a) (D.L.
0·356 pg/ml), interleukin (IL)-12p70 (D.L. 0·927 pg/ml) and
IL-2 (D.L. 4·422 mg/ml). Values below detection levels were
reported as being equal to the level of detection.
Statistical analysis
Non-parametric statistical analyses of the mRNA, nitrites or
protein expression levels among groups (non-CD, GFD-CD
or active CD) were performed using the Kruskal-Wallis one-
way analysis of variance test and the Mann–Whitney U-test.
The Wilcoxon matched paired test was used to compare
different culture conditions from the same patient. The level
of significance was fixed at P < 0·05.
Table 1. Coeliac disease (CD) patients treated on a gluten-free diet (GFD) (a) and non-coeliac patients (b) biopsy cultured in basal medium and IL-15
challenged. All treated CD patients had negative serology and no duodenal alterations.
(a) Case Age Gender Months on a GFD Duodenal mucosa Serology HLA-DQ Basal IL-15
GFD-CD 1 44 Female 18 Marsh 1 Negative DQ2 + -
GFD-CD 2 25 Female 54 Marsh 1 Negative DQ2 + -
GFD-CD 3 68 Female 123 Marsh 0 Negative DQ2 + +
GFD-CD 4 48 Female 18 Marsh 1 Negative DQ2 + -
GFD-CD 5 44 Female 12 Marsh 1 Negative DQ2 + -
GFD-CD 6 66 Female 14 Marsh 1 Negative DQ2 + -
GFD-CD 7 39 Female 13 Marsh 1 Negative DQ2 + -
(b) Case Age Gender Diagnosis Basal IL-15
Non-CD 1 33 Female Functional dyspepsia –
Non-CD 2 58 Female Functional dyspepsia –
Non-CD 3 53 Female Hiatus hernia –
Non-CD 4 60 Female Chronic gastritis –
Non-CD 5 53 Female Functional dyspepsia –
Non-CD 6 60 Male Functional dyspepsia –
Non-CD 7 73 Female Functional dyspepsia –
Non-CD 8 69 Female Functional dyspepsia –
Non-CD 9 56 Female Chronic gastritis –
Non-CD 10 23 Female Functional dyspepsia –
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Results
Higher IL15Ra mRNA expression in CD patients
IL15Ra mRNA expression was studied in non-cultured
biopsy explants from CD patients, both on GFD and on
a gluten-containing diet, and non-CD healthy controls.
Neither gender- nor age-related effects were observed in any
case (data not shown). Figure 1 shows that the expression of
IL15Ra mRNA is higher in CD patients, with independence
of gluten ingestion (CD patients on GFD, median 4·320 U;
CD patients on a gluten-containing diet, median 7·921 U),
when compared with non-CD controls (median 0·795 U,
P = 0·0334 and P = 0·0062, respectively). No statistical differ-
ences were found between CD patients on GFD and on a
gluten-containing diet (active), which discards higher values
because of inflammation, and points to a constitutive and/or
primary condition in CD patients. In a similar way, no cor-
relation was found between the degree of histological lesion
in a gluten-containing diet patient or the months on a GFD
in treated patients with the expression of IL15Ra. Finally, it
is noteworthy that the IL15Ra mRNA expression shows a
bi-modal distribution, as can be observed in the non-CD
group. Therefore, the few cases in the latter group with
detectable levels of IL15Ra were in the range of CD patients.
Tissue IL15Ra expression in CD patients
Confocal microscopy analysis confirmed previous results of
higher IL15Ra expression in CD patients. Thus, a large
number of IL15Ra+ cells were identified within the epithelia,
lamina propria and crypt area, in sections from CD patients
on a gluten-containing diet (Fig. 2a). On the contrary, rare
positive cells, located within the lamina propria, were
observed in normal tissue (Fig. 2b). IL15Ra was found
mainly associated with the nuclear membrane, as previously
Table 2. Cytokine primer sets, PCR products (bp, base pairs), temperature of annealing, and source of the primers used for quantitative PCR.
Molecule Primers sequence bp Annealing Primers source reference
b-actin fw: 5′ – ATG GGT CAG AAG GAT TCC TAT GTG – 3′ 359 60 23
rv: 5′ – CTT CAT GAG GTA GTC AGT CAG GTC – 3′
IL15Ra fw: 5′ – GCC AGC GCC ACC CTC CAC AGT AA – 3′ 402 70 24
rv: 5′ – GCC AGC GGG GGA GTT TGC CTT GAC – 3′
iNOS fw: 5′ – TCT GCA GAC ACG TGC GTT ACT – 3′ 115 56 25
rv: 5′ – ATG CAC AGC TGA GCA TTC CA – 3′
IFNg fw: 5′ – TGG AAA GAG GAG AGT GAC AG – 3′ 129 60 26
rv: 5′ – ATT CAT GTC TTC CTT GAT GG – 3′
TNFa fw: 5′ – TCA GAT CAT CTT CTC GAA CC – 3′ 361 60 27
rv: 5′ – CAG ATA GAT GGG CTC ATA CC – 3′
Fig. 1. Intestinal expression of IL15Ra mRNA
in arbitrary units (U) in non-cultured biopsy
explants from non-CD healthy controls
(C, n = 22), and CD patients, both on
gluten-free diet (GFD, n = 20) and on a diet
containing gluten (active, n = 19). Only
isoforms non-secreted and carrying exon 3 are
detected. Statistically significant differences are
shown (P < 0·05 Krustal-Wallis one-way
analysis of variance test and two-tailed
Mann–Whitney U-test). Horizontal bars


























Higher IL-15 response in CD patients
67© 2008 British Society for Immunology, Clinical and Experimental Immunology, 154: 64–73
reported [28]. As only those isoforms lacking exon 2 (unable
to bind IL-15) do not co-localize with the nuclear membrane,
our results confirm the existence of differences in a biologi-
cally active IL15Ra between CD and non-CD individuals.
Based on the morphology and location of IL15Ra+ cells, it
can be concluded that in the intestinal mucosal of CD
patients, these cells belong to different lineages.
IL15Ra mRNA expression is triggered by in vitro IL-15
stimulation of biopsy explants from non-CD patients
Next, we performed functional studies addressing the modu-
lation of IL15Ra by IL-15 stimulation of biopsies from both
non-CD (10 patients) and CD patients on GFD (7 patients).
After organ culture in basal conditions, whole protein biopsy
explants were tested for IL-15 by Western blot. Basal IL-15
production was only found in one CD patient, who was
discarded from the study in order to correctly measure the
IL-15 response to an exogenous stimulus (Fig. 3). Therefore,
IL-15 stimulation was performed in 6 GFD-CD and 10
non-CD patients. After 3 h of IL-15 stimulation and 21 extra
h of culture in basal conditions, IL15Ra expression was
only triggered in non-CD patients (Fig. 4a) (basal condi-
tions median, 0·100 U; IL-15 stimulation median, 1·204 U;
P = 0·0313), but not in CD patients (basal conditions median,
6·350 U; IL-15 stimulation median, 10·400 U; P = n.s.).
Fig. 2. Comparison of IL15Ra intestinal
expression by confocal immunofluorescence: (a)
coeliac patient and (b) non-coeliac healthy
control. IL15Ra was mainly found associated




c 1 2 3 c 4 5 6
Fig. 3. Representative Western blot analysis using whole protein biopsy explants after 24 h of basal culture in non-coeliac controls (lanes 1–3)
and treated coeliac disease patients (lanes 4–6). C: human recombinant IL-15 lane. No detectable levels of IL-15 were found in the non-CD patients,
while only one out of seven CD patients on GFD was positive for this cytokine (lane 6).
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Increased immunological response to in vitro IL-15
stimulation in treated CD patients
Organ cultures of biopsy explants were also performed
to investigate whether the higher expression of IL15Ra
observed in CD patients could be involved in a higher IL-15
response in these patients. Interestingly, after only 3 h of
stimulation, innate mediators (i.e. nitrites) were already
increased in CD cultures (basal conditions median, 5·753 mg/
ml; IL-15 stimulation median, 7·694 mg/ml; P = 0·0313), but
not in non-CD (basal conditions median, 8·204 mg/ml; IL-15
stimulation median, 6·876 mg/ml) (Fig. 4b). Moreover, at the
end of the culture (24 h), the pro-inflammatory mediator
IFNg was also triggered only in CD patients after IL-15
stimulation (basal conditions median, 0·5424 pg/ml; IL-15
stimulation median, 41·420 pg/ml; P = 0·0313) (Fig. 4c),
but no changes were observed in non-CD patients (basal
conditions median, 0·5424 pg/ml; IL-15 stimulation median,
2·281 pg/ml). On the other hand, TNFa was reported to be
increased, although borderline significant in CD, in both
non-CD (basal conditions median, 0·4969 pg/ml; IL-15
stimulation median, 3·456 pg/ml; P = 0·0156) and CD
patients (basal conditions median, 0·2560 pg/ml; IL-15
stimulation median, 4·840 pg/ml; P = 0·0625) (Fig. 4d).
Finally, neither IL-2 (non-CD patients, basal conditions
median, 4·422 pg/ml, IL-15 stimulation median, 4·422 pg/
ml; CD patients, basal conditions median, 4·422 pg/ml,
IL-15 stimulation median, 5·262) (Fig. 4e) nor IL-12p70
levels (non-CD patients basal conditions median, 0·927 pg/
ml, IL-15 stimulation median, 0·927 pg/ml; CD patients,
basal conditions median, 0·927 pg/ml, IL-15 stimulation
median, 1·103) (Fig. 4f) were modified after stimulation
with IL-15.
Increased basal expression in vitro of
pro-inflammatory mediators in treated CD patients
After discarding differences in the secretion of inflammatory
mediators (nitrites, IFNg, TNFa, IL-2 and IL-12p70) when
culture d (cultured) in basal conditions between CD and
non-CD patients (data not shown), we next investigated
whether the higher CD-specific response to IL-15 could
occur not only as a consequence of a higher expression of its
receptor, but also due to a higher basal expression of the
precursors of these mediators (mRNA). Thus, mRNA
















































































































































































































































































































































































































































































































































































Fig. 4. Organ culture of duodenal biopsy samples: in vitro expression of IL15Ra mRNA after 24 h (a); and secretion of nitrites (b), after 3 h, and
IFNg (c), TNFa (d), IL-2 (e) and IL-12p70 (f), after 24 h, from non-CD healthy controls (C, n = 10) and coeliac disease patients on GFD (n = 6), in
arbitrary units (U), both basal culture conditions and after IL-15 stimulation (3 h of stimulation + 21 h in basal conditions). Statistically significant
differences are shown (P < 0·05, Wilcoxon matched paired test). Horizontal bars indicate median and whiskers maximum and minimum values.
IQR: interquartile range.
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and TNFa) were measured in 10 GFD-CD and 24 non-CD
patients after culture in basal conditions. TNFa mRNA
expression was similar in both groups (non-CD patients
median, 11·600 U; CD patients median, 3·008; Fig. 5a).
However, the basal expression of both iNOS (non-CD
patients median, 0·454 U; CD patients median, 5·026;
P = 0·040 Fig. 5b) and IFNg (non-CD patients median,
2·265 U; CD patients median, 297·2; P = 0·020; Fig. 5c) was
found to be higher in CD patients.
Discussion
In this paper we report for the first time, to our knowledge,
that CD patients on GFD respond more efficiently to IL-15
stimulation than non-CD individuals. We have also con-
firmed a higher expression of IL15Ra in the duodenum of
CD patients, as previously reported by Di Sabatino et al.
[11]. The number of cells expressing IL15R was strikingly
higher in CD patients on a gluten-containing diet, as com-
pared with controls (Fig. 2). As location and morphology of
positive cells were different, it also seemed clear that distinct
cell lineages may express IL15Ra in the intestinal mucosa.
Interestingly, most of the IL15Ra expression was mainly
found to be associated with the nuclear membrane, as
previously reported [28]. Thus, our data point to a higher
expression of IL-15 binding receptor in the CD duodenum,
and as only biologically active isoforms co-localize with the
nuclear membrane [28], this may lead to a higher response
to IL-15 in CD patients. As a consequence, and according to
the two-signal model of CD immunopathogenesis [7], we
propose that the first IL-15-related signal induced by gliadin
would trigger more easily the development of the disease in
CD patients.
Although previous studies have suggested that IL-15
remains increased in the mucosa of CD patients on GFD
[14,29], our results have revealed that the higher expression
of its receptor is independent of IL15, because it was almost
absent in CD patients on GFD. These results confirm
previous observations from our group suggesting that IL15
may have an early effect in triggering the innate response,
as assessed by both immunohistochemistry and Western
blot [30]. Considering that this higher expression of
IL15Ra is independent of IL-15 or the inflammatory con-
dition of the intestine, our data point to the existence of
primary differences and, probably, to a new possible genetic
factor involved in the CD immunopathogenesis.
Interestingly, the precursors of the effector molecules only
triggered in CD (i.e. nitrites and IFNg) were found to be also
increased in CD patients on GFD. Although these data could
question the real ‘remission state’ of the biopsies, all patients
were reported as Marsh 0–1 at the time of the biopsy, and
had negative serology for at least 1 year, therefore pointing
out to a completely recovered mucosa. Moreover, TNFa,
which is induced in both groups, shows no differences in
expression. It has been recently proposed that intraepithelial
lymphocytes are also an important source of IFNg [31,32],
and its production persists even after the introduction of the
GFD [32]. Moreover, IFNg can also be an inducer of iNOS
[33], and, therefore, this may explain the finding of an
increased expression of both precursors in treated CD
samples. As a consequence, the increased basal expression of
both IL15Ra, and IFNg and iNOS found in our samples, can
all together lead to a higher response to IL-15, resulting in a
decreased immunological threshold response and the induc-
tion of the secondary pro-inflammatory signal. Therefore
the higher expression of IL15Ra would be another predis-
posing factor in the development of CD. It is noteworthy that
most of the CD samples, both from treated and untreated
patients, expressed IL15Ra (85·71% of treated, 78·91% of
CD patients on a gluten-containing diet), while only 45·45%
of the non-CD samples had detectable levels of the precursor
(Fig. 1). Moreover, the IL15Ra expression in the CD patients
did not correlate with the degree of histological lesion in
untreated patients or the time on a GFD in treated patients,
so its higher expression seems to be constitutive. As a conse-
quence, IL15Ra expression is revealed as one of the minor-
effect predisposing factors involved in the CD pathogenesis



































































Fig. 5. Organ culture of duodenal biopsy samples: in vitro expression of TNFa (a), iNOS (b) and IFNg (c) mRNA in arbitrary units (U) in biopsy
explants from non-CD healthy controls (C, n = 23) and treated coeliac disease patients (GFD, n = 10) after 24 h of basal culture. Statistically
significant differences are shown (P < 0·05, two-tailed Mann–Whitney U-test). Horizontal bars indicate median values. IQR: interquartile range.
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hypersecretion, etc.) acting all in conjunction with the main
HLA-DQ2/DQ8 factor.
Although innate immunity plays a key role in the devel-
opment of CD, no specific innate factors have been described
so far (TG2 and HLA-DQ2/DQ8 elicit their function in the
secondary adaptive response). Moreover, there is a growing
evidence about the direct toxic effect of gliadin in several
biological models. It has been reported that gliadin induces
rearrangements of the cytoskeleton, disassembling the
integrity of the tight-junction system through a zonulin-
dependent manner, not only in epithelial cell lines like
Caco-2 cells [34,35], IEC-6 cells [13,35] or the LoVo multi-
celullar system [36], but also in non-coeliac biopsies chal-
lenged in vitro with gliadin [35]. Gliadin is also a potent
stimulus for antigen presenting cells like monocytes,
macrophages and dendritic cells, in both humans and mice
[37–40]. Moreover, gliadin exerts a direct cytotoxic effect in
several human cell lines by inhibiting cell growth and reduc-
ing cell viability [37,41–43] and, in Caco-2 cells, gliadin
inhibits DNA and RNA synthesis [44,45], and induces apo-
ptosis [46,47]. These results, suggesting a generalized innate-
triggering effect of gliadin by a still unknown innate-gliadin
receptor, led us to study the existence of an innate IL-15
response to gliadin in both CD and non-CD patients by
using a biopsy culture model [20].
However, this model does not seem to reflect the in vivo
situation, where the gliadin-induced IL-15 should be
expected to have some biological effects in non-CD indi-
viduals (thought not enough for triggering the adaptive
response), as suggested by the finding of IL-15 not only
in the whole protein biopsy explants but even in culture
supernatants after gliadin challenge, which excludes an intra-
cellular storage of the cytokine. Therefore, after a normal
gluten-containing meal, some IL-15-driven effects should
be expected in all individuals (i.e. dendritic cell activa-
tion, intraepithelial lymphocyte NK-like reprogramming,
increased tight-junction-mediated permeability, or entero-
cyte apoptosis through NKG2D-MICA interaction). Never-
theless, gliadin seems to be well tolerated by the majority of
the general population and the features mentioned above are
specific for CD patients. In consequence, the induced produc-
tion of IL-15 might be not as biologically active in non-CD
patients as observed in CD patients.
The results shown here, the increased expression of both
IL15Ra and pro-inflammatory mediators, and the higher
response to IL-15, support the hypothesis that CD patients
have a lower IL-15 threshold response. This hypothesis may
explain why the (innate) IL-15-mediated response to gluten
is not restricted to CD, though the secondary inflammatory
response is only observed in genetically susceptible CD
patients. This lower threshold is probably elicited by the
higher density of IL-15Ra, amongst other predisposing
factors. If we consider that gliadin-induced IL-15 is peak-
triggered following meals, and therefore is not a constant
stimulus, we can understand how IL-15 would induce the
expression of its receptor in non-CD individuals (Fig. 4a).
On the other hand, in CD patients the gliadin-triggered
IL-15 would not be used to induce its expression, which
remains already increased, and might therefore be directly
active. Moreover, it has been recently observed, by using a
mice model [48], that IL15Ra positive cells can capture and
stably store IL-15 molecules as intracellular reservoirs
through recycling, which then provide an environment with
a prolonged release of biologically active IL-15. Therefore,
the higher IL15Ra expression in CD may act as a persistent
IL-15 reservoir for the surrounding microenvironment and
thus magnify its effects in the CD intestine.
In conclusion, we suggest a model in which gliadin trig-
gers an IL-15 innate response in all individuals [20]. To
explain why the IL-15 response is not so efficient in non-CD
individuals, or at least in those genetically predisposed
patients (HLA-DQ2/DQ8), we propose the existence of a
lower IL-15 immunological threshold in CD patients for the
triggering of the inflammatory response. This lower thresh-
old would probably be mediated by the higher IL15Ra
expression, amongst other not yet determined factors, like a
higher basal expression of other immune mediators. This
situation renders the intestine of CD patients more suscep-
tible to IL-15 and to the development of the secondary
inflammatory response, whereas in non-CD individuals, the
gliadin-triggered IL-15 would not reach the threshold level
necessary to elicit the secondary immune response.
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